Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
The EU certification will support supplies of drug products registered in Europe, from this manufacturing site
Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg and 40 mg had annual sales of USD 42 mn in the United States (IQVIA MAT April 2023)
In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone
For the treatment of Superficial Femoral Artery
The product is expected to be launched in June 2023
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
Single dose of Ferric Carboxymaltose (FCM) up to 750 mg of iron can be infused in 15 minutes
Farxiga is expected to have such a strong influence on the market due to the impressive results
ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer
Subscribe To Our Newsletter & Stay Updated
